NASDAQ:COEP

Coeptis Therapeutics (COEP) Stock Forecast, Price & News

$1.07

0.00 (0.00%)

(As of 09/28/2023 ET)

Compare

Today's Range: $1.03
▼
$1.12
50-Day Range: $0.82
▼
$1.30
52-Week Range: $0.81
▼
$21.42

Volume: 61,969 shs
Average Volume: 214,708 shs
Market Capitalization: $26.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.33

Coeptis Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 301.2% Upside
$4.33 Price Target
Short Interest: Healthy
0.41% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.18
Based on 6 Articles This Week
Insider Trading: Acquiring Shares
$40,994 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

480th out of 975 stocks

Biological Products, Except Diagnostic Industry

73rd out of 162 stocks

3.5

Analyst's Opinion

Consensus Rating
Coeptis Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.33, Coeptis Therapeutics has a forecasted upside of 301.2% from its current price of $1.08.
Amount of Analyst Coverage
Coeptis Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.41% of the float of Coeptis Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Coeptis Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Coeptis Therapeutics has recently increased by 31.54%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Coeptis Therapeutics does not currently pay a dividend.
Dividend Growth
Coeptis Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for COEP.

2.3

News and Social Media Coverage

News Sentiment
Coeptis Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Coeptis Therapeutics this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Coeptis Therapeutics to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Coeptis Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $40,994.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
36.60% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 13.26% of the stock of Coeptis Therapeutics is held by institutions.

0.0

Earnings and Valuation

Price to Book Value per Share Ratio
Coeptis Therapeutics has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Coeptis Therapeutics (NASDAQ:COEP) Stock

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.

COEP Price History

30 days | 90 days | 365 days | Advanced Chart

COEP Stock News Headlines

September 27, 2023 | finance.yahoo.com

Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa

September 24, 2023 | americanbankingnews.com

LADENBURG THALM/SH SH Initiates Coverage on Coeptis Therapeutics (NASDAQ:COEP)

September 28, 2023 | Micro-Cap Stock Trader (Ad)

Unlock the treasure on Mount Olympus with this little-known mining stock.

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

September 23, 2023 | americanbankingnews.com

Head to Head Review: Coeptis Therapeutics (NASDAQ:COEP) vs. Coherus BioSciences (NASDAQ:CHRS)

September 20, 2023 | msn.com

Seattle biotech startup Deverra Therapeutics raising cash to develop cellular immunotherapies

September 14, 2023 | finance.yahoo.com

Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection

September 11, 2023 | finance.yahoo.com

Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment

September 5, 2023 | bizjournals.com

Coeptis appoints Colleen Delaney as chief scientific and medical officer

September 28, 2023 | Micro-Cap Stock Trader (Ad)

U.S. drive to onshore battery supply chains could create big winners in lithium

Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons

August 30, 2023 | finance.yahoo.com

Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer

August 17, 2023 | baystreet.ca

Coeptics Flat on Deverra Deal

August 17, 2023 | finance.yahoo.com

Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics

August 1, 2023 | finance.yahoo.com

Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic

July 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Mirati Therapeutics (MRTX), Clearside Biomedical (CLSD)

June 16, 2023 | finance.yahoo.com

Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering

June 14, 2023 | benzinga.com

Coeptis Therapeutics Holdings, Inc. Announces Pricing Of $3.5M Underwritten Offering

June 14, 2023 | finance.yahoo.com

Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

June 12, 2023 | markets.businessinsider.com

EF Hutton Sticks to Its Buy Rating for Jasper Therapeutics (JSPR)

June 9, 2023 | bizjournals.com

Coeptis Therapeutics to join Nasdaq Capital Market next Monday

June 9, 2023 | finance.yahoo.com

Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market

May 30, 2023 | benzinga.com

Coeptis Therapeutics Shares Rally 67% In May, Clinical Interests And Planned Acquisitions Attract The Interest ($COEP)

May 17, 2023 | finance.yahoo.com

Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer

May 11, 2023 | markets.businessinsider.com

JonesTrading Keeps Their Buy Rating on Coeptis Therapeutics Holdings (COEP)

May 10, 2023 | finance.yahoo.com

Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications

April 19, 2023 | msn.com

JonesTrading Initiates Coverage of Coeptis Therapeutics Holdings (COEP) with Buy Recommendation

April 19, 2023 | msn.com

Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023

April 18, 2023 | msn.com

Coeptis Rises on Key Assets Acquisition from Deverra

See More Headlines

Receive COEP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coeptis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

COEP Company Calendar

Today: 9/28/2023
Next Earnings (Estimated): 11/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:COEP
CUSIP: N/A
CIK: 1759186
Web: coeptispharma.com
Phone: 724-934-6467
Fax: N/A
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.33
High Stock Price Forecast: $6.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +305.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-37,570,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -1,949.40%
Return on Assets: -144.14%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 1.51
Quick Ratio: 1.51

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 336.25
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.25 per share
Price / Book: 4.28

Miscellaneous

Outstanding Shares: 25,140,000
Free Float: 15,939,000
Market Cap: $26.90 million
Optionable: Not Optionable
Beta: -0.69

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. David Mehalick (Age 54)
Co-Founder, Chairman, CEO & Pres
Comp: $361.62k

Ms. Christine Elise Sheehy (Age 56)
Co-Founder and VP of Compliance & Corp. Sec.
Comp: $226k

Mr. Daniel Alexander Yerace (Age 40)
Co-Founder, VP of Operations & Director
Comp: $360.35k

Mr. Brian Cogley M.B.A. (Age 37)
Chief Financial Officer

Dr. Colleen Delaney M.D. (Age 55)
M.Sc., MSc, CSO & Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

COEP Stock - Frequently Asked Questions

Should I buy or sell Coeptis Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coeptis Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" COEP shares.
View COEP analyst ratings or view top-rated stocks.
What is Coeptis Therapeutics' stock price forecast for 2023?: 3 Wall Street analysts have issued 12 month target prices for Coeptis Therapeutics' stock. Their COEP share price forecasts range from $3.00 to $6.00. On average, they expect the company's stock price to reach $4.33 in the next year. This suggests a possible upside of 305.0% from the stock's current price.
View analysts price targets for COEP or view top-rated stocks among Wall Street analysts.
How have COEP shares performed in 2023?: Coeptis Therapeutics' stock was trading at $1.5313 at the beginning of the year. Since then, COEP stock has decreased by 30.1% and is now trading at $1.07.
View the best growth stocks for 2023 here.
Are investors shorting Coeptis Therapeutics?: Coeptis Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 58,800 shares, an increase of 31.5% from the August 31st total of 44,700 shares. Based on an average trading volume of 58,600 shares, the short-interest ratio is presently 1.0 days. Currently, 0.4% of the shares of the company are short sold.
View Coeptis Therapeutics' Short Interest.
When is Coeptis Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 27th 2023.
View our COEP earnings forecast.

What is Coeptis Therapeutics' stock symbol?: Coeptis Therapeutics trades on the NASDAQ under the ticker symbol "COEP."
Who are Coeptis Therapeutics' major shareholders?: Coeptis Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Creative Planning (2.99%), Geode Capital Management LLC (0.47%), Shaolin Capital Management LLC (0.21%) and Ionic Capital Management LLC (0.21%). Insiders that own company stock include Chris Calise and Gene Salkind.
View institutional ownership trends.
How do I buy shares of Coeptis Therapeutics?: Shares of COEP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Coeptis Therapeutics' stock price today?: One share of COEP stock can currently be purchased for approximately $1.07.
How much money does Coeptis Therapeutics make?: Coeptis Therapeutics (NASDAQ:COEP) has a market capitalization of $26.90 million and generates $80,000.00 in revenue each year.
How can I contact Coeptis Therapeutics?: Coeptis Therapeutics' mailing address is 801 S POINTE DRIVE SUITE TH-1, MIAMI BEACH FL, 33139. The official website for the company is coeptispharma.com. The company can be reached via phone at 724-934-6467 or via email at bborden@tiberend.com.

This page (NASDAQ:COEP) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial